News

U.S. Food and Drug Administration Approves Selinexor (XPOVIO) for Diffuse Large B-cell Lymphoma

Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.

U.S. Food and Drug Administration Approves Tazemetostat (TAZVERIK) and EZH2 Mutation Test for Follicular Lymphoma

Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).

Meet the 2020 Lymphoma Clinical Mentoring Program Scholars

The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.

Bridging the Gap in Adolescent and Young Adult Lymphoma

Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.

An Emerging Cancer: Survivors Advocate for Women’s Health and Awareness

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is impacting women globally—leaving many questions for both patients and providers.

In the Business of Giving Back

Being a socially responsible company helps businesses “do good” while building credibility among its customers and employees.

Strength in Unity, Strength in Hope – A Message From Meghan Gutierrez, LRF CEO

Dear Friends, As I celebrate lymphoma survivors and their loved ones this month – National Cancer Survivors Month – and the incredible progress in lymphoma research that has made a month like this possible, I am also reminded that our…

Why the U.S. Needs Non-Profits Now More Than Ever

By Michael Werner and Christina Kazhe The COVID-19 pandemic has brought the country to a crawl. Lawmakers and consumers alike are rightly worried about the economic security of shuttered bars, restaurants, and retail locations. But many have largely ignored the…

LRF Establishes COVID-19 Financial Assistance Grant For Patients

The Foundation's new COVID-19 Financial Assistance Grant can help eligible lymphoma/CLL patients receive limited financial assistance to help cover out-of-pocket costs related to their care.

U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.